At an investor R&D day in New York, French drugmaker Sanofi (Euronext: SAN) provided an update on developments regarding its pipeline and what it expects to be key growth drivers in the future.
The firm said it has 12 new molecular entities with blockbuster potential, which it plans to take forward alongside a strategy of maintaining strong growth from existing assets.
Anticipating a “steady stream of potential blockbuster launches,” Sanofi said recently launched and future pharma assets could generate as much as $11 billion in annual sales by 2030.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze